September 8, 2016 - The court approved the settlement and entered the orders approving the plan of allocation, the motion for attorneys’ fees and expenses, and dismissing the action with prejudice.
May 23, 2016 - The court preliminarily approved the settlement.

May 5, 2016 - Parties filed a stipulation of settlement.

March 4, 2015 - The court denied the defendants' motion to dismiss.

August 14, 2014 - The defendants filed a motion to dismiss.

June 27, 2014 - The lead plaintiff filed an amended complaint.

May 16, 2014 - The lead plaintiff and lead counsel were appointed and all cases were consolidated.

April 22, 2014 - Lead plaintiff motions were filed.

February 21, 2014 - An investor in shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) filed a lawsuit in the U.S. District Court for the Southern District of New York against Intercept Pharmaceuticals Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between January 9, 2014 and January 10, 2014.

According to the complaint the plaintiff alleges on behalf of all persons or entities who purchased or otherwise acquired securities of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) between January 9, 2014 and January 10, 2014, that Intercept Pharmaceuticals Inc and certain of its officers and directors violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

More specifically, the plaintiff claims that on January 9, 2014 and January 10, 2014, Intercept Pharmaceuticals Inc announced that its Phase 2 trial of OCA for the treatment of NASH had been stopped early for efficacy based on an interim analysis that showed that the efficacy endpoint of the trial had been met and that as a result of the Company's announcements, Intercept Pharmaceuticals Inc’s stock price skyrocketed from a January 8, 2014 close of $72.39 per share to a January 10, 2014 close of $445.83 per share.

On January 9, 2014, Intercept Pharmaceuticals Inc announced that the FLINT clinical trial study of obeticholic acid (OCA) was stopped early for efficacy after a planned interim analysis showed the primary endpoint had been met. OCA is being developed by Intercept Pharmaceuticals Inc for the treatment of nonalcoholic steatohepatitis. On this news announcement, shares of Intercept Pharmaceuticals Inc increased over 500% over the next two trading sessions.

After the market close on Friday, January 10, 2014, The Wall Street Journal issued a report via a statement made by the National Institutes of Health stating that patients treated with Intercept Pharmaceuticals Inc's OCA in the clinical trial experienced lipid abnormalities, higher levels of bad LDL cholesterol and lowers levels of good HDL cholesterol, compared to patients treated with placebo.

On Sunday, January 12, 2014, Intercept Pharmaceuticals Inc made an announcement providing additional details of the OCA study including the lipid abnormalities disclosed in The Wall Street Journal report. In midday trading on Tuesday, January 14, 2014, the stock has traded down as much as $210.83 or 47% since the announcement made on Sunday.